This study investigates T(2)* quantification in carotid plaques before and after the administration of
ultrasmall superparamagnetic iron oxide particles (USPIOs) in a cohort of patients receiving
statin therapy. Phantom studies were performed using
gels with varying concentrations of USPIOs. In the phantom study, 12
gels were prepared with a range of freely distributed concentrations of
USPIO nanoparticles (0-0.05 mg/mL). Relative signal intensity measurements were obtained from a T(2)*-weighted sequence as well as quantitative T(2)* (qT(2)*) measurements. In the patient study, 40 patients with >40%
carotid stenosis were randomised to low- and high-dose
statin therapy (10 and 80 mg of
atorvastatin). Pre- and post- (36 h)
USPIO-enhanced MRI were performed at baseline, and at 6 and 12 weeks. A linear mixed-effects model was applied to account for the inherent correlation of multiple-plaque measurements from the same patient and to assess dose-response differences to
statin therapy. In the phantom study, the T(2)*-weighted sequence demonstrated an initial increase (T(1) effect), followed by a decrease (T(2)* effect), in relative signal intensity with increasing concentrations of
USPIO. The qT(2)* values decreased exponentially with increasing concentrations of
USPIO. In the patient study, there was a highly significant difference in post-
USPIO T(2)* measurements in plaques between the low- and high-dose
statin groups. This was observed for both the difference in qT(2)* measurements (post-
USPIO minus pre-
USPIO) (p < 0.001) and for qT(2)* post-
USPIO only (p < 0.001). The post-
USPIO qT(2)* values were as follows: baseline: low dose, 13.6 ± 5.5 ms; high dose, 12.9 ± 6.2 ms; 6 weeks: low dose, 13.3 ± 6.7 ms; high dose, 14.3 ± 7.7 ms; 12 weeks: low dose, 14.0 ± 7.6 ms; high dose, 18.3 ± 11.2 ms. It can be concluded that qT(2)* measurements provide an alternative method of quantifying
USPIO uptake. These results also demonstrate that changes in
USPIO uptake can be measured using post-
USPIO imaging only.